India Pharma Races to Capture Share of $142 Billion Patent Expiry Wave

India’s pharmaceutical industry is positioning itself for one of its biggest growth opportunities in years as a wave of patent expirations on blockbuster medicines worth nearly $142 billion in annual global sales opens the door for a new generation of generic drugs and biosimilars.

A report by CareEdge Ratings estimates that Indian drugmakers could capture between $3 billion and $5 billion in additional revenue over the next five years as dozens of high-value medicines lose market exclusivity between 2026 and 2030, creating fresh export opportunities in the United States, Europe and other major healthcare markets.

The coming “patent cliff” is expected to be one of the largest the pharmaceutical industry has seen in decades. Unlike earlier waves dominated by conventional medicines, more than 60% of the drugs approaching patent expiry are biologics — complex therapies used to treat cancer, autoimmune diseases, diabetes, obesity and neurological disorders.

For India, the shift presents both an opportunity and a test.

The country already supplies roughly one-fifth of the world’s generic medicines by volume and has built a reputation as a low-cost manufacturing hub. However, capturing the next phase of growth will require companies to move beyond traditional generics into sophisticated biosimilars that demand advanced manufacturing, regulatory expertise and significant research investment.

“India’s pharmaceutical industry is entering a new chapter,” analysts said, noting that future success will depend less on low-cost production and more on scientific capabilities, speed-to-market and regulatory execution.

Among the highest-profile drugs approaching patent expiry are Merck’s cancer immunotherapy Keytruda, Pfizer’s breast cancer treatment Ibrance and Johnson & Johnson’s multiple myeloma therapy Darzalex. Together, these medicines generate tens of billions of dollars in annual sales globally.

Indian pharmaceutical companies including Lupin, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Zydus Lifesciences, Intas Pharmaceuticals and Natco Pharma are among those positioning themselves to compete for market share as patents expire.

Oncology represents the largest opportunity, accounting for approximately 35% of the drugs losing exclusivity through 2030. Immunology follows at 24%, while diabetes, obesity and neurological therapies collectively account for nearly 30% of the upcoming patent cliff.

Industry executives say the race has already begun.

Several Indian companies are investing heavily in biosimilar pipelines, strategic partnerships and manufacturing capacity to secure early entry into lucrative markets. Zydus, through its partnership with Germany’s Formycon, is developing a biosimilar version of Keytruda, while Dr. Reddy’s has partnered with China’s Shanghai Henlius to commercialize a biosimilar of Darzalex in regulated markets.

The stakes are high because first movers often gain a significant advantage. Once physicians adopt a biosimilar and patients are stabilized on treatment, switching therapies becomes less likely, helping early entrants build market share.

Still, the opportunity comes with considerable risks.

Developing a biosimilar can cost between $100 million and $300 million and take as long as seven to nine years. Patent litigation, regulatory hurdles and competition from global rivals in South Korea, China and Europe could delay launches and compress margins.

Originator drug companies are also expected to aggressively defend their franchises through secondary patents, new formulations and legal challenges designed to extend exclusivity beyond core patent expirations.

Despite those obstacles, analysts believe the next five years could accelerate India’s transformation from the world’s pharmacy for low-cost generics into a leading supplier of high-value specialty medicines.

If Indian companies successfully navigate regulatory, legal and technological challenges, the approaching patent cliff could become one of the industry’s most significant growth catalysts since the generic drug boom that established India as a global pharmaceutical powerhouse.

Related posts:

India Stays on U.S. IP Watch List, Pharma Patent Divide Persists India Confronts ‘Profit-First’ Drug Pricing as Multinational Pharma Firms Accused of Exploiting Regulatory Gaps Trump’s 100% Pharma Tariffs Put Spotlight on India’s $10 Bn Drug Exports, Branded Generics in Grey Zone Opinion: India and the Global South